Artificial intelligence learns to recognize subtle biochemical features of γ-secretase substrates. Screening potential transmembrane proteins identifies 250 substrates, including 160 novel ones. These ...

In Alzheimer’s disease, some microglia gather around plaques, while others seem aloof, opting to keep their distance. In the July 14 Nature Neuroscience, scientists led by Marco Prinz at the ...

κWhen microglia wind up with a belly full of lipid droplets, it’s a sign that the cells are rallying, perhaps in vain, to a neurodegenerative threat. But according to a study published July 10 in Cell ...

Discover a comprehensive list of brain banks worldwide, facilitating Alzheimer's and Parkinson's research on Alzforum.

Big Data Insights: Blood Signatures of Cognitive Decline, Aging, APOE4 RESEARCH NEWS 2025-07-23 Research News In the “omics” era, where bigger is better, the Global Neurodegeneration Proteomics ...

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

In a watershed moment for the field, the U.S. Food and Drug Administration today approved the first Alzheimer’s treatment that tackles the underlying disease pathology. Biogen and Eisai’s anti-amyloid ...

After years of fits and starts, anti-amyloid immunotherapies are finally hitting their target effectively. At least four drugs have now demonstrated the ability to clear plaques from the brain: ...

Time to rewrite the brain anatomy textbook? In addition to the outermost dura, middle arachnoid, and innermost pia membranes surrounding the brain, researchers led by Kjeld Møllgård, University of ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Lecanemab binds protofibrils more tightly than fibrils, perhaps explaining lower ARIA rate. Use of plasma biomarkers brings down trial screening cost. Lecanemab has been selected for the first amyloid ...

After decades of nonstarters, blood tests for Alzheimer’s disease are finally here, enabling researchers to predict who may have amyloid plaques in their brain. Among the candidate tests jostling for ...